Lv31
240 积分 2022-12-16 加入
Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group
22天前
已完结
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
1个月前
已完结
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
2个月前
已完结
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
2个月前
已完结
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
2个月前
已完结
Fedratinib as an alternative to splenectomy for refractory splenomegaly prior to transplant for myelofibrosis
4个月前
已完结
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
4个月前
已完结
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study
4个月前
已完结
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
4个月前
已完结
Clinical characteristics and survival of extranodal natural killer/T-cell lymphoma: a single-center 12-year retrospective analysis
4个月前
已完结
皖公网安备34019202002308
